Eli Lilly and Company announced that its experimental obesity drug, retatrutide, produced weight loss in women across all stages of menopause [1].
The results are significant because post-menopausal women often face higher health risks from excess weight. By targeting this specific demographic, the company aims to position the drug as a first-in-class therapy for obesity in women experiencing hormonal shifts [2].
Data from late-stage clinical trial analyses indicated that participants in the phase-3 trial lost up to 30% of their body weight [3]. The company presented these findings to U.S. regulators and investors to support its application for a priority review from the U.S. Food and Drug Administration [2].
According to the company, the drug met most criteria for the FDA's new national priority voucher program [2]. This program is designed to accelerate the review process for medications that address unmet medical needs.
The announcement regarding the trial results was made on May 5, 2024 [2]. The company is now seeking to secure the priority review to bring the treatment to the U.S. market more quickly.
Retatrutide is part of a broader effort by Eli Lilly to expand its portfolio of weight-loss medications. The company said the drug's efficacy across various stages of menopause suggests a broad utility for women facing metabolic challenges related to aging [1].
“Participants in the phase-3 trial lost up to 30% of their body weight.”
The focus on menopausal women represents a strategic shift toward precision medicine in obesity treatment. Because menopause causes metabolic changes that make weight loss more difficult through diet and exercise alone, a drug proven effective across these stages could capture a significant and underserved market segment while potentially reducing long-term comorbidities associated with menopausal weight gain.
